Lipid lessening drugs overview

Haider Fathi Abd-Alkareem; Ahmed Haider Jaber; Ali Qasim Ibrahim; Murtadha Abdulhamid Fanok

doi:10.30574/gscbps.2020.10.1.0004

Authors

Haider Fathi Abd-Alkareem College of Pharmacy, Al-Nahrain University, Iraq.
Ahmed Haider Jaber College of Pharmacy, Al-Nahrain University, Iraq.
Ali Qasim Ibrahim College of Pharmacy, Al-Nahrain University, Iraq.
Murtadha Abdulhamid Fanok College of Pharmacy, Al-Nahrain University, Iraq.

DOI:

https://doi.org/10.30574/gscbps.2020.10.1.0004

Keywords:

Dyslipidemias, Statin, Fenofibrate, Coronary arteries disease

Abstract

Lipid lessening drugs are groups of drugs used to treat the conditions or diseases that associated with elevated blood levels of lipids (cholesterol, triglyceride) and low-density lipoprotein (LDL). These conditions known as dyslipidemias, which is hypercholesterolemia, hypertriglyceridemia, or combined hyperlipidemia. Many studies found that dyslipidemias inclined and increase the risk of other diseases such as atherosclerosis, diabetes mellitus, and coronary arteries disease.

Metrics

Metrics Loading ...

References

Rada FH. (2017). Association of lipid fractions levels with cardiovascular disease. Asian Journal of Pharmaceutical and Clinical Research, 10(3), 180-182.

Rada FH, Hasan NA and Al Baghdadi MH. (2015). Hepatotoxicity of Combined Therapy of Atorvastatin with Platelet P2Y12-ADP Receptor Antagonist in Coronary Heart Disease Treated Patients. The Iraqi Postgraduate Medical Journal, 14(1), 108- 113.

Hasan NA, Al Baghdadi MH and Rada FH. (2014). Assessment of adverse effect of atorvastatin with platelet P2Y12-ADP receptor antagonist on platelets aggregation and renal function in coronary heart disease treated patients . International Journal of Research in Pharmacy and Chemistry, 4(2), 274-282.

Krukemyer JJ and Talbert RL. (1987). Lovastatin: a new cholesterol-lowering agent. Pharmacotherapy, 7, 198–210.

Hebert PR, Gaziano JM, Chan KS and Hennekens CH. (1997). Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. Journal of the American Medical Association, 278, 313–321.

Pahan K, Sheikh FG, Namboodiri AM and Singh I. (1997). Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. Journal of Clinical Investigation, 100, 2671–2679.

Rada FH. (2018). Oxidative stress and some inflammatory biomarkers in patients with coronary heart disease. European Journal of Pharmaceutical and Medical Research, 5(1), 9-12.

Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, et al. (1998). Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. Journal of Clinical Investigation, 101, 2711–2719.

Seabra MC. (1998). Membrane association and targeting of prenylated Ras-like GTPases. Cell Signal, 10, 167–172.

Bokoch GM and Knaus UG. (2003). NADPH oxidases: not just for leukocytes anymore. Trends in Biochemical Sciences, 28, 502–508.

Watts GF, Dimmitt SB. (1999). Fibrates, dyslipoproteinaemia and cardiovascular disease. Current Opinion in Lipidology, 10, 561–574.

Ozasa H, Miyazawa S, Furuta S, Osumi T and Hashimoto T. (1985). Induction of peroxisomal beta-oxidation enzymes in primary cultured rat hepatocytes by clofibric acid. Journal of Biochemistry (Tokyo), 97, 1273–1278.

Kliewer SA, Xu HE, Lambert MH and Willson TM. (2001). Peroxisome proliferator-activated receptors: from genes to physiology. Recent Progress in Hormone Research, 56, 239–263.

Rada FH. (2019). Peroxisome proliferator - activated receptors family overview. European Journal of Pharmaceutical and Medical Research, 6(1), 167-170.

Chu R, Lin Y, Rao MS and Reddy JK. (1995). Cooperative formation of higher order peroxisome proliferator activated receptor and retinoid X receptor complexes on the peroxisome proliferator responsive element of the rat hydratase-dehydrogenase gene. Journal of Biological Chemistry, 270, 29636–39.

Rada FH. (2016). Fenofibrate adverse effects versus atorvastatin. International Journal of Research in Pharmacy and Chemistry, 6 (1), 32-37.

Reddy JK, Goel SK, Nemali MR, Carrino JJ, Laffler TG, Reddy MK, et al.(1986). Transcription regulation of peroxisomal fatty acyl-CoA oxidase and enoyl-CoA hydratase/3-hydroxyacyl-CoA dehydrogenase in rat liver by peroxisome proliferators. Proceedings of the National Academy of Sciences of the United States of America, 83, 1747–51.

Yu S, Rao S and Reddy JK. (2003). Peroxisome proliferator-activated receptors, fatty acid oxidation, steatohepatitis and hepatocarcinogenesis. Current Molecular Medicine, 3, 561–572.

Reddy JK and Hashimoto T. (2001). Peroxisomal beta-oxidation and peroxisome proliferator-activated receptor alpha: an adaptive metabolic system. Annual Review of Nutrition, 21, 193–230.

Staels B, Schoonjans K, Fruchart JC and Auwerx J. (1997). The effects of fibrates and thiazolidinediones on plasma triglyceride metabolism are mediated by distinct peroxisome proliferator activated receptors (PPARs).Biochimie, 79, 95–99.

Daynes RA and Jones DC. (2002). Emerging roles of PPARs in inflammation and immunity. Nature Reviews Immunology, 2,748–759.

Banks WA, Coon AB, Robinson SM, Moinuddin A, Shultz JM, Nakaoke R, et al. (2004). Triglycerides induce leptin resistance at the blood-brain barrier. Diabetes, 53, 1253–1260.

Toruner F, Akbay E, Cakir N, Sancak B, Elbeg S, Taneri F, et al. (2004). Effects of PPAR gamma and PPAR alpha agonists on serum leptin levels in diet-induced obese rats. Hormone and Metabolic Research, 36, 226–230.

Rao MS, Subbarao V and Reddy JK. (1986). Peroxisome proliferator-induced hepato-carcinogenesis : histochemical analysis of ciprofibrate-induced preneoplastic and neoplastic lesions for gammaglutamyl transpeptidase activity. Journal of the National Cancer Institute, 77,951–956.

Alsheikh-Ali AA, Kuvin JT and Karas RH. (2004). Risk of adverse events with fibrates. American Journal of Cardiology, 94, 935–938.

Gonzalez FJ, Peters JM and Cattley RC. (1998). Mechanism of action of the nongenotoxic peroxisome proliferators: role of the peroxisome proliferator-activator receptor alpha. Journal of the National Cancer Institute, 90, 1702–1709.

Steinmetz KL. (2002). Colesevelam hydrochloride. American Journal of Health-System Pharmacy, 59, 932–939.

Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, Lin Y, Brockmeyer M, et al. (2015). Effects of proprotein convertase subtilisin/kexin type 9 antibodies in adults with hypercholesterolemia: a systematic review and meta-analysis. Annals of Internal Medicine, 163, 40-51.

Vasudevan AR and Jones PH. (2005). Effective use of combination lipid therapy. Current Cardiology Reports, 7, 471–479.

Lipid- lowering drugs. (2016). Medical Letter on Drugs and Therapeutics, 58 (1506), 133-40.